In a stun­ner, Mer­ck lands pos­i­tive PhI­II for its CETP out­cast anace­trapib

Long af­ter many an­a­lysts had giv­en Mer­ck’s CETP heart drug anace­trapib up for dead fol­low­ing a slate of ex­pen­sive buri­als for the first three drugs in the class, the phar­ma gi­ant man­aged to shock the in­dus­try this morn­ing with news that their drug came through a 30,000-pa­tient study with con­vinc­ing da­ta of its ef­fec­tive­ness.

In a brief state­ment on the topline re­sults, the phar­ma gi­ant not­ed that its drug sig­nif­i­cant­ly re­duced the risk of a coro­nary event – a com­pos­ite of coro­nary death, my­ocar­dial in­farc­tion, and coro­nary revas­cu­lar­iza­tion – among high-risk pa­tients who had al­ready been through LDL-low­er­ing ther­a­py ef­fec­tive­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.